Guerbet (France) sales up as contrast agent phased out
This article was originally published in Clinica
Guerbet (France) has decided to drop its Telebrix 38 contrast agent and recall stocks in France and abroad over the next few months. The product withdrawal follows several reports to the Agence du Medicament of product crystallisation. The agency asked for some batches to be removed, but Guerbet has withdrawn the product as "a cautious move", Philippe Barthelet, Guerbet's financial director, told Clinica. He says no instances of clinical problems have been reported.